Miami, Florida – Global Stem Cells Group (GSCG), an international organization focused on advancing regenerative medicine, is pleased to announce what it expects will be the expansion of its operations into Brazil through a new strategic representation agreement with Julius Ladeira. This collaboration is anticipated to bring the full scope of GSCG’s divisions—including ISSCA (International Society for Stem Cell Application) and CELLGENIC, its biologics manufacturing arm—into one of the most dynamic healthcare markets in Latin America.
A New Chapter for Regenerative Medicine in Brazil
Brazil, home to more than 600,000 physicians, has long been recognized as a country with significant potential for regenerative medicine. It is estimated that nearly 50,000 physicians are already engaged in preventive and regenerative practices, with approximately 30,000 incorporating these approaches into their daily work. GSCG believes that the introduction of its educational programs, biologic products, and network of centers of excellence may help align Brazil more closely with the latest global developments in cellular therapies.
“We are hopeful that this new representation will mark the beginning of a long-term partnership that benefits both physicians and patients in Brazil,” said Benito Novas, CEO of Global Stem Cells Group, Founder of ISSCA and CELLGENIC. “For years, many Brazilian physicians have traveled abroad to train with ISSCA and to access advanced technologies. Now, we expect to bring these opportunities directly into the country, creating local access to training, certification, and biologic solutions.”
Local Leadership for National Impact
The agreement appoints Julius Ladeira as the official representative of Global Stem Cells Group in Brazil. He will oversee the introduction of ISSCA educational programs, CELLGENIC’s biologic products, and GSCG’s broader initiatives into the local market.
“It is with great satisfaction that we welcome ISSCA, CELLGENIC, and the Global Stem Cells Group into Brazil,” said Julius Ladeira. “We expect this partnership to be of great importance not only for the Group but also for Brazil as a whole. Our market has extraordinary potential, and we believe this initiative may bring real opportunities for growth and collaboration.”
Upcoming Conference in São Paulo
As part of this expansion, ISSCA has already scheduled its first major educational event in Brazil, set to take place in São Paulo on October 2–3, 2025. The conference is expected to bring together national and international experts, providing physicians with access to hands-on training, certification programs, and the latest insights in regenerative medicine.
“We are hopeful that this event will serve as the first of many collaborative milestones in Brazil,” added Novas. “Our expectation is to create a sustainable platform where education and innovation can come together for the benefit of physicians and their patients.”
About Global Stem Cells Group and CELLGENIC
Founded in 2010 and headquartered in Miami, USA, Global Stem Cells Group (GSCG) is a biotechnology consortium with operations in more than 40 countries. Its divisions cover clinical research, physician education, and biologics commercialization.
Its flagship brand, CELLGENIC, offers a portfolio of regenerative medicine products—including exosomes, MSCs, platelet-rich plasma kits, and other cellular solutions—produced under rigorous quality protocols. Through ISSCA, its educational division, GSCG provides certification programs, workshops, and international conferences that are expected to support the responsible adoption of regenerative therapies.
Global Stem Cells Group is a publicly traded company operating under the symbol RMTG.
More information:
www.stemcellsgroup.com | www.issca.us
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
